Jingkun Zeng
曾京昆
Jingkun Zeng (曾京昆) is co-founder and CTO of EonArk (无尽方舟), an AI longevity biotech startup he founded in May 2026 in Shenzhen with CEO Zhao Simiao, working from cross-species aging research toward healthspan extension using data, AI, and biotech. He did postdoctoral research at UC Berkeley under CRISPR pioneer and Nobel laureate Jennifer Doudna, and, per Unity Ventures, was first author of a Nature paper proposing a new cancer therapeutic approach published around June 2026.
AI-generated — may contain errors, please verify.
Coverage
AI longevity biotech startup EonArk raises two rounds in one month, with Unity Ventures leading seed+ round | Unity Ventures portfolio
Oxford PhD Launches Startup, Using Data, AI, and Biotechnology to Explore the Future of Longevity and Health
Unity Ventures Early Bet Momenta Files for Hong Kong IPO, Over a Dozen Portfolio Companies Announce Funding Rounds | Unity Ventures Summer Review
From Embodied Artificial Intelligence and world models to controlled nuclear fusion and quantum computing, the frontier of exploration knows no bounds.
Endless Ark Co-Founder Publishes Breakthrough Cancer Research in Nature, Proposing New Therapeutic Approach | Unity Ventures Portfolio
A New CRISPR Therapeutic Strategy Brings New Hope to Previously Undruggable Cancers
Immortality: Starting with Dogs
Death is not an inevitable law of nature — just an engineering problem.
